MARKET NEWS

Nkarta Therapeutics Reports Potent Natural Killer Cell Anti-Cancer Activity in Preclinical Tumor Model
Alligator Bioscience & Aptevo Therapeutics Present New Preclinical Data
Moleculin Announces New Independent Study Expands Potential Use of Its Pancreatic Drug Candidate
Entera Bio Reports Positive Results from Part 1 of a Phase 2 PK/PD Study
Intensity Therapeutics Highlights Data in Advanced Solid Tumors
Codexis Announces Results of Phase 1a Clinical Trial

  FEATURED EDITORIAL

  COMPANY PROFILE

Credence MedSystems is setting a new standard in drug delivery, helping you differentiate your products through innovative delivery systems while preserving your trusted processes. Simple, safe, and intuitive usability creates a better, safer experience for patients and healthcare professionals. Innovative designs provide safety activation clicks, end-of-dose feedback cues, and automatic needle retraction—without changes to familiar injection procedures. Our unique product innovations coexist with your existing processes, avoiding disruption to your filling lines and simplifying your secondary packaging operations. Use the primary container and components of your choice. Maintain your preferred sourcing strategy and manufacturing processes. Click here for more.

 

 

Ajinomoto Bio-Pharma Services is a fully integrated contract development and manufacturing organization, with sites in Wetteren and Balen, Belgium and San Diego, California, USA, providing comprehensive process development services, cGMP manufacturing and drug product fill finish services of small molecule and biologic APIs and intermediates. Ajinomoto Bio-Pharma Services offers a broad range of innovative platforms and capabilities to rapidly scale from clinical and pilot programs to commercial quantities, including: Corynex technologies, oglionucleotide synthesis, antibody drug conjugations (ADC), high potency APIs (HPAPI), continuous flow manufacturing and more. Ajinomoto Bio-Pharma Services is dedicated to providing a high level of quality and service to meet our client’s needs. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Enable Injections Enters Strategic Partnerships With UCB & Apellis

Enable Injections Enters Strategic Partnerships With UCB & Apellis

Enable Injections, Inc., a patient-centric drug delivery combination product company developing advanced wearable devices for subcutaneous delivery of high-volume therapeutics, recently announced it has entered into development agreements with Apellis Pharmaceuticals, and most recently, UCB.

Organovo Partners With IIAM on Multi-Year Clinical Biomaterial Sourcing Agreement 

Organovo Partners With IIAM on Multi-Year Clinical Biomaterial Sourcing Agreement 

Organovo Holdings, Inc. recently announced it has entered into a cell and tissue clinical sourcing agreement with the International Institute for the Advancement of Medicine (IIAM).

Microfluidic Modulation Spectroscopy (MMS) For Protein Therapeutic Drug Analysis

Microfluidic Modulation Spectroscopy (MMS) For Protein Therapeutic Drug Analysis

Automated, high sensitivity spectroscopic analyses for the development, formulation and manufacture of biotherapeutics are now available thanks to RedShiftBio’s new AQS3pro protein characterization platform. The system is based on Microfluidic Modulation Spectroscopy (MMS) technology. Read this application note to learn about how MMS characterizes higher order protein structures, the mechanisms of protein stability, aggregation, protein similarity and quantitation.

Nemera’s e-Novelia® Ophthalmic Add-On Wins “Excellence in Pharma: Drug Delivery Devices” Award

Nemera’s e-Novelia® Ophthalmic Add-On Wins “Excellence in Pharma: Drug Delivery Devices” Award

A team of industry experts awarded Nemera’s electronic add-on for ophthalmic droppers with a prestigious CPhI Award for Best Drug Delivery Device in its category.

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

November 21 – Analytical Instruments
November 28 – Polymers & Biomaterials